CN1954845A - 一种肿节风复方药物组合物及其制备方法 - Google Patents
一种肿节风复方药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1954845A CN1954845A CN 200510104372 CN200510104372A CN1954845A CN 1954845 A CN1954845 A CN 1954845A CN 200510104372 CN200510104372 CN 200510104372 CN 200510104372 A CN200510104372 A CN 200510104372A CN 1954845 A CN1954845 A CN 1954845A
- Authority
- CN
- China
- Prior art keywords
- extract
- injection
- caulis marsdeniae
- marsdeniae tenacissimae
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 61
- 241000736026 Sarcandra Species 0.000 title claims description 24
- 239000002131 composite material Substances 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 title description 7
- 239000000284 extract Substances 0.000 claims abstract description 235
- 239000003814 drug Substances 0.000 claims abstract description 100
- 238000000034 method Methods 0.000 claims abstract description 29
- 239000007924 injection Substances 0.000 claims description 126
- 238000002347 injection Methods 0.000 claims description 126
- 239000010263 Marsdeniae tenacissimae extract Substances 0.000 claims description 94
- 229940079593 drug Drugs 0.000 claims description 88
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 239000000890 drug combination Substances 0.000 claims description 26
- 239000012567 medical material Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 238000000605 extraction Methods 0.000 claims description 14
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 12
- 150000007965 phenolic acids Chemical class 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 11
- HOEVRHHMDJKUMZ-UHFFFAOYSA-N Isofraxidin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2OC HOEVRHHMDJKUMZ-UHFFFAOYSA-N 0.000 claims description 10
- ANCHXLMTFNOVDK-UHFFFAOYSA-N Isofraxidin Natural products COC1=C(O)C(OC)=CC2=C1OC=CC2=O ANCHXLMTFNOVDK-UHFFFAOYSA-N 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 10
- 229930182470 glycoside Natural products 0.000 claims description 10
- 150000002338 glycosides Chemical class 0.000 claims description 10
- 235000009048 phenolic acids Nutrition 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 7
- 235000001671 coumarin Nutrition 0.000 claims description 7
- 150000004775 coumarins Chemical class 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 150000007524 organic acids Chemical class 0.000 claims description 7
- 239000001530 fumaric acid Substances 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 85
- 230000008569 process Effects 0.000 abstract description 9
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 abstract description 3
- 240000006509 Gynostemma pentaphyllum Species 0.000 abstract description 2
- 240000004274 Sarcandra glabra Species 0.000 abstract description 2
- 229940090044 injection Drugs 0.000 description 124
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 102
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 69
- 239000000243 solution Substances 0.000 description 67
- 238000012360 testing method Methods 0.000 description 61
- 241000699670 Mus sp. Species 0.000 description 57
- 230000002401 inhibitory effect Effects 0.000 description 45
- 229960004756 ethanol Drugs 0.000 description 37
- 239000000706 filtrate Substances 0.000 description 34
- 230000000694 effects Effects 0.000 description 33
- 238000003756 stirring Methods 0.000 description 28
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 26
- 229960004397 cyclophosphamide Drugs 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000010297 uvangoletin Substances 0.000 description 21
- 239000008215 water for injection Substances 0.000 description 21
- 239000000796 flavoring agent Substances 0.000 description 18
- 235000019634 flavors Nutrition 0.000 description 18
- 239000008187 granular material Substances 0.000 description 18
- 239000008354 sodium chloride injection Substances 0.000 description 18
- 238000002512 chemotherapy Methods 0.000 description 16
- 238000005516 engineering process Methods 0.000 description 16
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 16
- 229920000053 polysorbate 80 Polymers 0.000 description 16
- 238000003556 assay Methods 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 15
- 239000013558 reference substance Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 14
- 201000007270 liver cancer Diseases 0.000 description 14
- 208000014018 liver neoplasm Diseases 0.000 description 14
- 238000004064 recycling Methods 0.000 description 14
- 230000001476 alcoholic effect Effects 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000005303 weighing Methods 0.000 description 12
- 238000012856 packing Methods 0.000 description 11
- 238000001959 radiotherapy Methods 0.000 description 11
- 238000001694 spray drying Methods 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 239000011265 semifinished product Substances 0.000 description 9
- 206010003445 Ascites Diseases 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 201000009030 Carcinoma Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000007689 inspection Methods 0.000 description 7
- 238000004321 preservation Methods 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000007901 soft capsule Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 229940023488 pill Drugs 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 239000007779 soft material Substances 0.000 description 6
- 239000008227 sterile water for injection Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000005262 decarbonization Methods 0.000 description 4
- 229940093181 glucose injection Drugs 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 239000003182 parenteral nutrition solution Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000009287 sand filtration Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000007766 cera flava Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 239000013505 freshwater Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- -1 sheet Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 239000008347 soybean phospholipid Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 229940013618 stevioside Drugs 0.000 description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 3
- 235000019202 steviosides Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000005325 percolation Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 235000012950 rattan cane Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000011003 system suitability test Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 241000758719 Chloranthaceae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001065361 Gynostemma Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 241001125690 Marsdenia tenacissima Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- YEZWWUMWIFKEQM-UHFFFAOYSA-N O.OC.ClC(Cl)Cl.CCOC(C)=O Chemical compound O.OC.ClC(Cl)Cl.CCOC(C)=O YEZWWUMWIFKEQM-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 235000010842 Sarcandra glabra Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 231100001157 chemotherapeutic toxicity Toxicity 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- GLMWWMZIEZJGMT-UHFFFAOYSA-N chloroform;formic acid;propan-2-one Chemical compound OC=O.CC(C)=O.ClC(Cl)Cl GLMWWMZIEZJGMT-UHFFFAOYSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930187479 gypenoside Natural products 0.000 description 1
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- BLKQDSMHWQPNJU-UHFFFAOYSA-N n-(cyanomethyl)-n-(furan-2-ylmethyl)-3,4-dimethoxybenzenesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)N(CC#N)CC1=CC=CO1 BLKQDSMHWQPNJU-UHFFFAOYSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011046 pyrogen test Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别(有效成分) | 给药剂量(mg/kg) | 药材份数比 | 平均瘤重(g) | 抑瘤率(%) |
氯化钠注射液组 | 1ml | - | 2.32±0.37 | - |
注射用环磷酰胺 | 40 | - | 0.85±0.52*** | 63.4 |
肿节风注射液 | 60 | - | 1.66±0.43* | 28.4 |
通关藤注射液 | 60 | - | 1.65±0.39* | 28.9 |
(肿节风+通关藤)各配比注射液 | 6060606060606060606060 | 500+100001000+1001000+2001000+20001500+1001500+2001500+20005000+1005000+2005000+200010000+50 | 1.53±0.71*0.98±0.47**0.97±0.53**1.11±0.49**1.05±0.52**0.87±0.41***1.06±0.54**1.16±0.62**1.12±0.47**1.04±0.52**1.45±0.56* | 34.1ac57.8bd58.2bd52.2bd54.7bd62.5bd54.3bd50.0bd51.7bd55.2bd37.5ac |
组别 | 给药剂量(mg/kg) | 平均瘤重(g) | 抑瘤率(%) |
氯化钠注射液组肿节风注射液通关藤注射液绞股蓝注射液注射用环磷酰胺ZTJ注射液低剂量组ZTJ注射液中剂量组ZTJ注射液高剂量组 | 2ml120120120404080120 | 1.67±0.511.18±0.43*1.19±0.46*1.35±0.51*0.68±0.44***1.04±0.39*0.88±0.40**0.70±0.37*** | -29.328.719.159.335.9ace47.3bde58.8bde |
组别 | 给药剂量(mg/kg) | 平均瘤重(g) | 抑瘤率(%) | 增效率(%) | WBC(×109) | 胸腺指数 | 脾指数 |
空白对照组注射用环磷酰胺组注射用环磷酰胺+ZT注射液组A注射用环磷酰胺+ZT注射液组B注射用环磷酰胺+ZT注射液组C | -3030+2030+4030+60 | 2.16±0.391.23±0.28*1.01±0.31*0.81±0.27**0.62±0.22** | -43.553.2#62.5##71.2## | --22.343.763.8 | 8.68±2.213.27±1.63**6.41±1.46#7.07±1.53##7.69±1.70## | 25.46±5.5313.01±4.75**15.23±4.38#18.21±4.71##20.47±4.31## | 25.65±4.7310.02±2.48**16.42±3.21#18.25±3.62##19.96±4.57## |
组别 | 治疗 | 平均瘤重(g) | 抑瘤率(%) | 增效率(%) |
空白对照组60Co照射组60Co照射+ZTJ注射液组A60Co照射+ZTJ注射液组B60Co照射+ZTJ注射液组C | -0.05Gy/min0.05Gy+20mg/kg0.05Gy+40mg/kg0.05Gy+60mg/kg | 2.21±0.441.79±0.32*1.71±0.51*1.64±0.46**1.58±0.54** | -19.022.6#25.8##28.5## | --18.935.750.0 |
组别 | 给药剂量(mg/kg) | 生存天数(d) | 生命延长率(%) |
氯化钠注射液组肿节风注射液通关藤注射液ZTJ注射液低剂量组ZTJ注射液中剂量组ZTJ注射液高剂量组 | 2ml80804080120 | 12.2±4.115.4±2.7*14.8±2.7*16.5±3.2*17.4±3.9**18.5±4.6*** | -26.221.335.2ac42.6bd51.6bd |
批次 | 异秦皮啶含量(mg/g) | 反丁烯二酸含量(mg/g) | 药材重(kg) | 提取物重(g) | 得率(%) |
12345 | 1.031.141.191.061.22 | 0.2110.2420.2540.2370.282 | 601201202020 | 282727372544766254 | 4.712.282.123.831.27 |
批次 | 通关藤总酚酸含量(%) | 药材重(kg) | 提取物重(g) | 得率(%) |
123 | 30.1641.3445.21 | 204040 | 344392268 | 1.720.980.67 |
批次 | 绞股蓝总苷含量(%) | 药材重(kg) | 提取物重(g) | 得率(%) |
123 | 52.4157.9261.33 | 202020 | 774462413 | 3.872.312.07 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510104372XA CN1954845B (zh) | 2005-10-27 | 2005-10-27 | 一种肿节风复方药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510104372XA CN1954845B (zh) | 2005-10-27 | 2005-10-27 | 一种肿节风复方药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1954845A true CN1954845A (zh) | 2007-05-02 |
CN1954845B CN1954845B (zh) | 2012-03-07 |
Family
ID=38062517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200510104372XA Expired - Fee Related CN1954845B (zh) | 2005-10-27 | 2005-10-27 | 一种肿节风复方药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1954845B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412261A (zh) * | 2015-11-27 | 2016-03-23 | 深圳福山生物科技有限公司 | 一种药物组合物的用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1137721C (zh) * | 2002-03-21 | 2004-02-11 | 张平 | 一种治疗肝癌和大肠癌的中药注射液 |
CN1410110A (zh) * | 2002-11-19 | 2003-04-16 | 大连金港制药有限公司 | 含肿节风中药制剂作为制备治疗抗癌药物副作用药的应用 |
-
2005
- 2005-10-27 CN CN200510104372XA patent/CN1954845B/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105412261A (zh) * | 2015-11-27 | 2016-03-23 | 深圳福山生物科技有限公司 | 一种药物组合物的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN1954845B (zh) | 2012-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1954840A (zh) | 一种由绞股蓝、西洋参和黄芪制成的药物组合物 | |
CN1748765A (zh) | 一种具有通便排毒、减肥降脂功能的组合物及制备方法 | |
CN1245198C (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN1954868A (zh) | 治疗虚火上炎所致疾病的银菊清咽制剂及制法和质控方法 | |
CN101062084A (zh) | 一种抗肝炎的药物组合物 | |
CN1876039A (zh) | 治疗上呼吸道感染等疾病的药物制剂及制法和质控方法 | |
CN1958003A (zh) | 治疗慢性鼻炎及鼻窦炎的制剂及其制法和质控方法 | |
CN1954849A (zh) | 一种白花蛇舌草、人参和黄芪配伍的抗肿瘤的药物组合物 | |
CN1923241A (zh) | 包括淫羊藿提取物、钩藤提取物、天麻素的药物组合物及其制备方法和应用 | |
CN1879688A (zh) | 风热清制剂及其制备方法和质量控制方法 | |
CN1947747A (zh) | 由木犀草素和连翘制成的药物组合物及其制备方法和用途 | |
CN100341492C (zh) | 一种参芪降糖软胶囊及其制备检测方法 | |
CN101041004A (zh) | 一种新的抗肿瘤复方药物 | |
CN1954838A (zh) | 一种抗肿瘤的药物组合物 | |
CN1954870A (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN1954845A (zh) | 一种肿节风复方药物组合物及其制备方法 | |
CN1947749A (zh) | 一种由头花蓼和茯苓制成的药物组合物 | |
CN1954839A (zh) | 由通关藤、人参和黄芪制成的药物组合物 | |
CN1931233A (zh) | 一种用于治疗心脑血管疾病的丹参和淫羊藿的药用组合物 | |
CN1726928A (zh) | 一种治疗子宫肌瘤的药物组合物及其制备方法 | |
CN1939417A (zh) | 北豆根与金果榄或其提取物的药物组合物 | |
CN101073611A (zh) | 一种抗肿瘤的药物组合物 | |
CN1517326A (zh) | 栀子环烯醚萜总提物及其制备方法和用途 | |
CN1947765A (zh) | 由板蓝根和射干制成的药物组合物及其制备方法和用途 | |
CN101049336A (zh) | 一种新的抗癌药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: XUAN ZHU SHANDONG MEDICINE TECHNOLOGY CO. Free format text: FORMER OWNER: HUANG ZHENHUA Effective date: 20080530 |
|
C10 | Entry into substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080530 Address after: Tianchen Avenue Ji'nan High-tech Development Zone in Shandong province No. 2518 post encoding: 250101 Applicant after: Shandong Xuanzhu Medical Technology Co., Ltd. Address before: Post encoding No. 2518 block A, Tianchen Avenue Ji'nan High-tech Development Zone in Shandong Province: 250101 Applicant before: Huang Zhenhua |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAIAN SUSHI TECHNOLOGY TRANSFORMATION CENTER CO., Free format text: FORMER OWNER: SHANDONG XUANZHU MEDICAL TECHNOLOGY CO., LTD. Effective date: 20131008 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 250101 JINAN, SHANDONG PROVINCE TO: 226601 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131008 Address after: 226601 No. 8 Yingbin Road, software park, Haian County, Jiangsu Province Patentee after: Haian Su Fu Technology Transfer Center Co., Ltd. Address before: Tianchen Avenue in Ji'nan high tech Development Zone of Shandong province 250101 City No. 2518 Patentee before: Shandong Xuanzhu Medical Technology Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120307 Termination date: 20181027 |
|
CF01 | Termination of patent right due to non-payment of annual fee |